GlassScriptPhysician profile
Christopher G Potter
NPI 1043207657
$22,113.51
in general payments reported to CMS, 2019-2025
56 companies · $80.34 in 2025
The $80.34 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $12K · 2021: $1,739 · 2022: $1,999 · 2023: $2,255 · 2024: $2,002 · 2025: $80.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,235 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,235.41 |
| Education | $102.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,035.04 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $924.92 | 2019-2025 | |
| Biogen, INC. | $923.39 | 2019-2024 | Tysabri, Skyclarys, Vumerity |
| Abbvie INC. | $782.31 | 2021-2024 | |
| Amgen INC. | $708.49 | 2019-2023 | Aimovig |
| Teva Pharmaceuticals USA, INC. | $687.87 | 2019-2024 | Ajovy, Austedo Xr |
| Lundbeck LLC | $499.80 | 2019-2024 | Vyepti, Rexulti |
| Genentech USA, INC. | $478.80 | 2019-2024 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Genzyme Corporation | $456.76 | 2019-2022 | |
| Lilly USA, LLC | $407.06 | 2019-2024 | Amyvid, Emgality, Reyvow |
| Alexion Pharmaceuticals, INC. | $359.30 | 2019-2024 | Ultomiris, Soliris |
| Eisai INC. | $355.39 | 2019-2024 | |
| Emd Serono, INC. | $350.11 | 2019-2024 | Mavenclad |
| Horizon Therapeutics Plc | $330.80 | 2021-2023 | Uplizna |
| Allergan, INC. | $312.17 | 2019-2022 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Potter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.